| Community transmission and viral load kinetics of the SARS-CoV-2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal … A Singanayagam, S Hakki, J Dunning, KJ Madon, MA Crone, A Koycheva, ... The lancet infectious diseases 22 (2), 183-195, 2022 | 788 | 2022 |
| A global perspective on pyrazinamide resistance: systematic review and meta-analysis MG Whitfield, HM Soeters, RM Warren, T York, SL Sampson, EM Streicher, ... PloS one 10 (7), e0133869, 2015 | 168 | 2015 |
| The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis TM Walker, P Miotto, CU Köser, PW Fowler, J Knaggs, Z Iqbal, M Hunt, ... The Lancet Microbe 3 (4), e265-e273, 2022 | 138 | 2022 |
| Mycobacterium tuberculosis pncA Polymorphisms That Do Not Confer Pyrazinamide Resistance at a Breakpoint Concentration of 100 Micrograms per Milliliter in … MG Whitfield, RM Warren, EM Streicher, SL Sampson, FA Sirgel, ... Journal of clinical microbiology 53 (11), 3633-3635, 2015 | 44 | 2015 |
| Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment M Driesen, Y Kondo, BC de Jong, G Torrea, S Asnong, C Desmaretz, ... Clinical Microbiology and Infection 24 (1), 60-64, 2018 | 34 | 2018 |
| Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens E Rivière, MG Whitfield, J Nelen, TH Heupink, A Van Rie Clinical Microbiology and Infection 26 (10), 1332-1337, 2020 | 23 | 2020 |
| Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis MG Whitfield, EM Streicher, T Dolby, JA Simpson, SL Sampson, ... Tuberculosis 99, 128-130, 2016 | 22 | 2016 |
| Risk factors and vectors for SARS-CoV-2 household transmission: a prospective, longitudinal cohort study N Derqui, A Koycheva, J Zhou, TD Pillay, MA Crone, S Hakki, J Fenn, ... The Lancet Microbe 4 (6), e397-e408, 2023 | 18 | 2023 |
| The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis MG Whitfield, RM Warren, V Mathys, L Scott, E De Vos, W Stevens, ... Journal of Antimicrobial Chemotherapy 73 (10), 2667-2674, 2018 | 18 | 2018 |
| Prediction of pyrazinamide resistance in Mycobacterium tuberculosis using structure-based machine-learning approaches JJ Carter, TM Walker, AS Walker, MG Whitfield, GP Morlock, CI Lynch, ... JAC-Antimicrobial Resistance 6 (2), dlae037, 2024 | 14 | 2024 |
| Comparative performance of genomic methods for the detection of pyrazinamide resistance and heteroresistance in Mycobacterium tuberculosis MG Whitfield, DM Engelthaler, C Allender, M Folkerts, TH Heupink, ... Journal of clinical microbiology 60 (1), e01907-21, 2022 | 8 | 2022 |
| Discordances between molecular assays for rifampicin resistance in Mycobacterium tuberculosis: frequency, mechanisms and clinical impact A Van Rie, MG Whitfield, E De Vos, L Scott, P Da Silva, C Hayes, ... Journal of Antimicrobial Chemotherapy 75 (5), 1123-1129, 2020 | 8 | 2020 |
| Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene MG Whitfield, SAE Marras, RM Warren, A Van Rie, J Rice, LJ Wangh, ... Scientific reports 10 (1), 4234, 2020 | 8 | 2020 |
| Oral Class I and III antiarrhythmic drugs for maintaining sinus rhythm after catheter ablation of atrial fibrillation JJH Bray, M Warraich, MG Whitfield, CU Peter, R Baral, M Ahmad, ... The Cochrane Database of Systematic Reviews 2023 (3), 2023 | 6 | 2023 |
| Pyrazinamide resistance in Mycobacterium tuberculosis MG Whitfield Stellenbosch: Stellenbosch University, 2016 | 2 | 2016 |
| Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis S Omar, MG Whitfield, MB Nolan, JT Ngom, N Ismail, RM Warren, ... Journal of Antimicrobial Chemotherapy 79 (2), 211-240, 2024 | 1 | 2024 |
| A Surveillance Framework for Healthcare Associated Infections and Antimicrobial Resistance in Acute Care in the Context of COVID-19: A Rapid Literature Review and Expert Consensus N Zhu, T Rawson, R Ahmad, JR Price, M Gilchrist, SK Singh, S Tomczyk, ... | 1 | 2021 |
| Drug resistant tuberculosis cases from the Copperbelt province and Northern regions of Zambia: Genetic diversity, demographic and clinical characteristics NK Chisompola, EM Streicher, A Dippenaar, MG Whitfield, M Tembo, ... Tuberculosis 130, 102122, 2021 | 1 | 2021 |
| Association between genotypic and phenotypic pyrazinamide resistance in Mycobacterium tuberculosis MG Whitfield, EM Streicher, T York, I Mardarowicz, L Scott, W Stevens, ... International Journal of Infectious Diseases 21, 96, 2014 | 1 | 2014 |
| A pro-inflammatory gut mucosal cytokine response is associated with mild COVID-19 disease and superior induction of serum antibodies D Costigan, J Fenn, S Yen, N Ilott, S Bullers, J Hale, W Greenhalf, ... Mucosal immunology 17 (1), 111-123, 2024 | | 2024 |
Samantha SampsonStellenbosch UniversityVerified email at sun.ac.za
